is it illegal to compound semaglutide Readout Newsletter: Makary hearing, Hims, Nimbus, Ozempic Hims & Hers plans to

Chen, MD, Chief Medical Officer Number Of Employees: ~59 Stage: Publicly traded Financial Snapshot: The companys market cap as of July 2026 is $4.39 billion Key Products: VK2735 (subcutaneous), dual GLP-1/GIP receptor agonist in

Anyone with symptoms of hormone imbalance and lab confirmation: fatigue, weight gain, hot flashes, low libido, mood changes, sleep disruption, brain fog

Reference Rosenstock J et al

Compounded medications are NOT FDA-approved

Low testosterone accelerates muscle loss, increases visceral fat, and worsens metabolic outcomes

What can be said factually is that retatrutide is the one major GLP-1 with no legitimate, approved, or compounded supply anywhere, which means there is no safer tier to choose instead, only the clinical trial or the gray market